Case report of a gigantic recurrent angiomyolipoma in a horseshoe kidney
Authors:
Markéta Hulová; Michal Staník; Daniel Macík; Jan Doležel
Authors‘ workplace:
Oddělení urologické onkologie, Masarykův onkologický ústav, Brno
Published in:
Ces Urol 2020; 24(1): 69-73
Category:
Case report
Prezentujeme kazuistiku objemného recidivujícího angiomyolipomu podkovovité ledviny u mladé pacientky s podezřením na syndrom tuberózní sklerózy. Stav byl řešen opakovanou cytoredukční operací v kombinaci se systémovou léčbou mTOR inhibitory.
Overview
We present a case report of gigantic recurrent angiomyolipoma of the horseshoe kidney in a young patient with suspected tuberous sclerosis syndrome. The condition was solved by repeated cytoreductive surgery in combination of systemic treatment with mTOR inhibitors.
Keywords:
angiomyolipoma – tuberous sclerosis – horseshoe kidney – mTOR inhibitor
Sources
1. Flum AS, Hamoui N, Said MA, et al. Update on the Diagnosis and Management of Renal Angiomyolipoma. J Urol 2016; 195: 834–846.
2. Ürge T, Pitra T, Chudáček Z, et al. Nové trendy v léčbě renálního angiomyolipomu. Ces Urol 2015; 19(2): 106–117.
3. Fernández‑Pello S, Hora M, Kuusk T, et al. Management of sporadic renal angiomyolipomas: a systematic review of available evidence to guide recommendations from the European Association of Urology renal cell carcinoma guidelines panel. Eur Urol Oncol 2019 Jun 3. pii: S2588-9311(19)30054-9.
4. Paldus V, Šámal V, Mečl J, et al. Wunderlichův syndrom – soubor pacientů s netraumatickým spontánním krvácením do retroperitonea. Ces Urol 2019; 23: 230–236.
5. Hušek P, Košina J, Pacovský J, et al. Roboticky asistovaná resekce objemného angiomyolipomu levé ledviny. Ces Urol 2018; 22: 234–237.
6. Samuels JA. Treatment of renal angiomyolipoma and other hamartomas in patients with tuberous sclerosis complex. Clin J Am Soc Nephrol 2017; 12: 1196–1202.
7. Bhatt JR, Richard PO, Kim NS, et al. Natural history of renal angiomyolipoma (AML): most patients with large AMLs >4 cm can be offered active surveillance as an initial management strategy. Eur Urol 2016; 70: 85–90.
8. McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011; 364: 1595–1606.
9. Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus long‑term use in patients with tuberous sclerosis complex: four‑year update of the EXIST-2 study. PLoS One 2017; 12: e0180939.
10. Toriu N, Mizuno H, Sawa N, et al. Everolimus reduces the size of tuberous sclerosis complex‑related huge renal angiomyolipomas exceeding 20 cm in the longest diameter. Case Rep Oncol 2018; 11: 258–267.
Labels
Paediatric urologist Nephrology Urology Clinical oncologyArticle was published in
Czech Urology
2020 Issue 1
Most read in this issue
- Our experience with MRI/TRUS software fusion for targeted prostate biopsies
- Multi-resistant gram negative bacteria in urology
- Hereditary renal cell carcinoma syndromes
- Case report of a gigantic recurrent angiomyolipoma in a horseshoe kidney